(Q41559607)

3 October 2017

1 reference

title

Cost-benefit analyses in the health-care literature: don't judge a study by its label (English)

1 reference

3 October 2017

Zarnke KB

1

1 reference

3 October 2017

Levine MA

series ordinal

2

1 reference

3 October 2017

O'Brien BJ

series ordinal

3

1 reference

3 October 2017

publication date

1 July 1997

1 reference

Journal of Clinical Epidemiology

3 October 2017

published in

1 reference

3 October 2017

volume

50

1 reference

3 October 2017

issue

7

1 reference

3 October 2017

page(s)

813-822

1 reference

Cost-benefit and cost-effectiveness analysis in health care. Growth and composition of the literature

3 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Health care CBA/CEA: an update on the growth and composition of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Use and misuse of the term "cost effective" in medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-effectiveness league tables: More harm than good?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

The willingness to pay for in vitro fertilization: a pilot study using contingent valuation

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Assessing the economic value of a new antidepressant. A willingness-to-pay approach

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Economic evaluation in health care: is there a role for cost-benefit analysis?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Recombinant human erythropoietin vs transfusions in the treatment of anemia of prematurity. A cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-Benefit Analysis of Hepatitis-B Vaccination: A Computerized Decision Model for Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Social work services in the emergency department: a cost-benefit analysis of an extended coverage program

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Ovulation induction with gonadotropins and intrauterine insemination compared with in vitro fertilization and no therapy: a prospective, nonrandomized, cohort study and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Screening and treatment of asymptomatic bacteriuria of pregnancy to prevent pyelonephritis: a cost-effectiveness and cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Intensive fluoride varnish program in Swedish adolescents: economic assessment of a 7-year follow-up study on proximal caries incidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of walking to prevent coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Nutrition support team management of enterally fed patients in a community hospital is cost-beneficial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Intensive care costing methodology: cost benefit analysis of mask continuous positive airway pressure for severe cardiogenic pulmonary oedema.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of non-pharmacological treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Survival after severe brain injury in the aged

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of the work-up for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Laparoscopic surgery for ectopic pregnancies: technology assessment and public health implications

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Health education for pregnant smokers: its behavioral impact and cost benefit

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Prenatal WIC participation can reduce low birth weight and newborn medical costs: a cost-benefit analysis of WIC participation in North Carolina

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Economic assessment of maternal serum screening for Down's syndrome using human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of preconception care for women with established diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

The cost-benefits of a nursing demonstration project, Part III

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Costs and Benefits of Preemployment Drug Screening

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Comparison of prevention strategies for neonatal group B streptococcal infection. A population-based economic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost/benefit analysis of cardiopulmonary resuscitation: a comprehensive study--Part II

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of pharmacologic erection program (PEP) versus penile prosthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Expectant management of placenta previa: cost-benefit analysis of outpatient treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of hip fracture treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Does transurethral laser ureterolithotripsy justify its cost?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

A cost-benefit analisys of chagas disease control

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of laparoscopic versus laparotomy salpingo-oophorectomy for benign tubo-ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

The use of ketorolac in lumbar spine surgery: a cost-benefit analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost and outcome in a series of shunted premature infants with intraventricular hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of transesophageal echocardiography in cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Radiation therapy: a long term cost benefit analysis in a North American region

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost and risk benefit in the management of clinical stage II nonseminomatous testicular tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

An 18-month follow-up of a secondary prevention program for back pain: help and hindrance factors related to outcome maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Couples' willingness to pay for IVF/ET

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Self-managed versus agency-provided personal assistance care for individuals with high level tetraplegia.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

A cost-benefit analysis of legislation for bicycle safety helmets in Israel

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Folic acid fortification of grain: an economic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Health economic analysis of the neonatal screening program in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Screening women of childbearing age for human immunodeficiency virus. A cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Should college students be vaccinated against meningococcal disease? A cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of an educational program for general practitioners by the Swedish Committee for the Prevention and Treatment of Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for type 1 (insulin-dependent) diabetes mellitus in Moscow--blood glucose versus urine glucose self-monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

A self-management program for adult asthma. Part II: Cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of the introduction of mass vaccination against hepatitis B in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of general vaccination against Haemophilus influenzae type b in Sweden.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

A cost-benefit analysis of enforcement efforts to reduce serving intoxicated patrons

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Re-evaluation of a radiation protection cost benefit analysis study in brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

An assessment of overbadging at a large clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Should British soldiers be vaccinated against hepatitis A? An economic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Human immunodeficiency virus counseling, testing, referral, and partner notification services. A cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of laparoscopic adnexectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of screening for toxoplasmosis during pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomized drug trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Economic evaluation of hypertension treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Are people willing to pay for a community-based preventive program

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

More informative abstracts: current status and evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

Cost-benefit analysis of six alternative payment incentives for child therapists

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900064-4

7 January 2021

10.1016/S0895-4356(97)00064-4

Identifiers

DOI

1 reference

3 October 2017

1 reference